Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Vaccine
Go back to Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Vaccine| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 9.00 -0.13 (1.42%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.13 | 52 Week High | $9.23 | |||
| Open | $9.16 | 52 Week Low | $1.16 | |||
| Day High | $9.37 | P/E | N/A | |||
| Day Low | $8.97 | EPS | $-0.30 | |||
| Volume | 3,706,151 | |||||
